![Page 2: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/2.jpg)
Objectives of this lecture
By the end of this lecture you will be able to:1. Define the term “Gene Therapy”2. Use the correct terminology for gene transfer3. Realize the significance of gene therapy research
![Page 3: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/3.jpg)
Objectives of this lecture
By the end of this lecture you will be able to:1. Describe the different strategies for gene therapy2. Select the suitable strategy based on the clinical case3. Understand the complexity of clinical application of gene therapy4. Evaluate proposed strategies according to the therapeutic need
![Page 4: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/4.jpg)
What is gene therapy?
![Page 5: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/5.jpg)
What is gene therapy?
Introduction of new genetic material into a cell for therapeutic purposes
Genetic Materials:
DNA
RNA
![Page 6: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/6.jpg)
Problem Example Solution
Defect in protein expression G6PD deficiency Introduce a correct
version of the gene
Expression of harmful proteins Cancer Inhibit or block the
harmful proteins
![Page 7: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/7.jpg)
Advantages of gene therapy• Specificity• Can be either temporary or permanent• Localization• Low immunogenicity
![Page 8: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/8.jpg)
Gene Therapy
• Germ-Line Gene Therapy:• Introduction of genes into germ cells (sperm and ovum)
• Somatic Gene Therapy:• Introduction of genes into somatic cells
![Page 9: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/9.jpg)
Germ-Line Gene Therapy
• Hypothetically, germ-line therapy prevents transfer of defective genes to subsequent generation
• Due to ethical and safety reasons, it is not presently accepted for human application
• However, it is used for the transgenic laboratory animals production
![Page 10: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/10.jpg)
Gene therapy
In vivo Ex vivo
![Page 11: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/11.jpg)
Advantage DisadvantageSpecificity Time and labor consuming
High transfection efficiency Invasive
Contamination
Not every cell type is growable
![Page 12: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/12.jpg)
Ex vivo gene therapy• Most widely used in clinical trials
• Some attempts in practice
![Page 13: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/13.jpg)
Advantage Disadvantage
Low cost None specificity
None invasive Low transfection efficiency
Less contamination
![Page 14: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/14.jpg)
Ballistic DNA Injection (gene guns)
Invented for DNA transfer to plant cells
Fully applicable to eukaryotic cells
plasmid DNA shown here
![Page 15: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/15.jpg)
LiposomesNext level idea – why naked DNA?
Lets’ wrap it in something safe to increase transfection rate
Therapeutic drugs
Lipids – are an obvious idea !
![Page 16: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/16.jpg)
DNA delivery of genes by liposomes
Cheaper than viruses
No immune response
Especially good for in-lung delivery (cystic fibrosis)
100-1000 times more plasmid DNA needed for the same transfer efficiency as for viral vector
![Page 17: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/17.jpg)
In vivo gene therapy• Some organs are less suited for ex vivo e.g. (brain,
heart and lungs)
• More practical approach
![Page 18: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/18.jpg)
Gene Therapy Considerations• What gene will be delivered or targeted?• What method will be used?
• Genetic material either for gene expression or downregulation
• Vector to carry the genetic material inside the cells
Elements for gene transfer
![Page 19: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/19.jpg)
Expression Vector (Plasmid)
![Page 20: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/20.jpg)
Viral VectorNon-Viral Vector
![Page 21: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/21.jpg)
![Page 22: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/22.jpg)
Gene Transfer• Transformation: introduction of genetic materials into
bacteria
• Transfection: introduction of genetic materials into eukaryotic cells (e.g. fungi, plant, or animal cells)
• Transduction: introduction of genetic materials using viruses
• Lipofection: introduction of genetic materials using liposomes
![Page 23: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/23.jpg)
Stable vs. Transient Gene Transfer• Stable Gene Transfer: achieved by plasmid integration in the host
genome or episomal replication of the transferred plasmid.
• Transient Gene Transfer: the foreign DNA is usually not integrated into the nuclear genome and will be degraded or diluted through mitosis
![Page 24: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/24.jpg)
Gene Therapy Strategies
•Replacement of a missing or defective gene
•Introduction of gene(s) to influence cellular process
•Interference with gene products
![Page 25: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/25.jpg)
Replacement strategy
Applies to diseases caused by single gene defects
Transfer of a functional copy of the defective or missing gene
Examples: enzyme deficiencies
![Page 26: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/26.jpg)
Replacement strategy
To apply this strategy, three requirements must be met:
1. The specific gene defect must be known
2. A functional copy of the gene must be available
3. Target cells must be available and amenable to transfection methods resulting in long-term expression
![Page 27: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/27.jpg)
Replacement strategy
Gene with defect Disease/Disorder
Adenosine deaminase (ADA) SCID
a-1-antitrypsin Emphysema
CF transmembrane regulator Cystic fibrosis
Clotting factor VIII Hemophilia A
Clotting factor IX Hemophilia B
b-chain of hemoglobin Sickle cell anemia
![Page 28: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/28.jpg)
Mucus in bronchi is thick, interfering with lung function
1 in 25 are carriers
One of the first disorders to be actively studied for gene therapy.
Most lethal autosomal recessive disorder in U.S.
Cystic Fibrosis
![Page 29: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/29.jpg)
Based on: Harvard Family Health Guide, 1999
Sickle Cell Disease- recessive allele•Red blood cells are sickle shaped, issues with circulation causing anemia and pain
![Page 30: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/30.jpg)
Hemophilia
• A disorder in which a person’s blood does not clot properly.
• It is a recessive sex-linked, X-chromosome disorder.
• 1 in 10,000 males born are afflicted.
“Royalty Disease”
![Page 31: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/31.jpg)
ADA-deficient persons are affected by severe immunodeficiency, with recurrent infections that might be life-threatening.
First disease approved for gene therapy.
Autosomal recessive disorder.
The drug exists but is very expensive, needs to be injected in vein for life.
Adenoside Deaminase (ADA) Deficiency
Ashanti Disilva
![Page 32: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/32.jpg)
![Page 33: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/33.jpg)
Bubble Boy
David Phillip Vetter (September 21, 1971 – February 22, 1984)
![Page 34: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/34.jpg)
Gene therapy trial
First successful clinical trial in gene therapy was initiated in September 14, 1990
Hematopoietic stem cells were isolated from the patient (4 y/o girl) and transduced with retroviral vector containing ADA gene
25% recovery of normal ADA in patient T cells
![Page 35: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/35.jpg)
Why was ADA suitable?
Single gene defect
Gene was isolated and cloned in 1983
HSC are easy to obtain and maintain in vitro
![Page 36: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/36.jpg)
Influence strategy
Applies to complex disorders were more than one gene is involved
Based on in vitro cloning of human genes that were derived from human tissue
Examples: cancer
![Page 37: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/37.jpg)
Areas of investigation
Enhancement of anti-tumor response
Introduction of drug-resistance genes
Introduction of drug-sensitivity genes
Replacement of tumor suppressor genes
![Page 38: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/38.jpg)
Introduction of drug-sensitivity genes Suicide gene therapy
Gene that converts non-toxic prodrug into a toxic metabolite
Bystander effect
Gancyclovir triphosphate
Problem: it can transfect normal cells too
![Page 39: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/39.jpg)
Gene Therapy Strategies
•Replacement of a missing or defective gene
•Introduction of gene(s) to influence cellular process
•Interference with gene products
![Page 40: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/40.jpg)
Interference strategy
Downregulation of gene expression at the mRNA level
Inhibition of mRNA translation
![Page 41: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/41.jpg)
Interference nucleic acids
DNAAntisense oligodeoxynucleotide (ODN)DNAzyme
RNAAntisense RNARibozymeSmall interfering RNA (siRNA)Short hairpin RNA (shRNA)microRNA (miRNA)
RNA interference
(RNAi)
![Page 42: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/42.jpg)
DNAzyme
![Page 43: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/43.jpg)
DNAzyme binds target mRNA
mRNA cleavage and degradation
DNAzyme
AAAAAA….ATarget mRNA
protein
X
© American Society for Investigative Pathology
![Page 44: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/44.jpg)
Ribozyme
![Page 45: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/45.jpg)
Antisense ODN
• Sequence-selective oligonucleotide that can bind to a target mRNA to inhibit gene expression i.e. to inhibit translation
![Page 46: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/46.jpg)
Antisense ODN
![Page 47: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/47.jpg)
Antisense ODNAntisense ODN
mRNA
RNase H
![Page 48: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/48.jpg)
We don’t have antisense ODN for every disease
• The main barrier to antisense strategy is optimal delivery in sufficient quantities to the correct target and for the desired time frame to achieve the desired level of gene inhibition
• ODNs are polyanionic macromolecule (large and charge)
• Stability issues in vivo
![Page 49: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/49.jpg)
Designing Biologically Stable ODNs
![Page 50: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/50.jpg)
Designing Biologically Stable ODNs
![Page 51: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/51.jpg)
![Page 52: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/52.jpg)
Fomivirsen Sodium (Vitravene)®
• FDA-approved for the local treatment of CMV retinitis in AIDS patients
![Page 53: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/53.jpg)
Fomivirsen Sodium (Vitravene)®• Dose 150-330 μg intravitreal injection
• Every other week for 2 doses
• Cleared locally by exonucleases 1-2 hr after injection
![Page 54: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/54.jpg)
Antisense RNA
![Page 55: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/55.jpg)
What is RNAi?
• Post-transcriptional phenomenon that was initially discovered in plants
• Mediated by double-stranded RNA
![Page 56: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/56.jpg)
siRNA
RISC
siRNA is bound by RISC and unwound by RNA helicase
RISC
Sense RNA strand degraded
© American Society for Investigative Pathology
![Page 57: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/57.jpg)
RISC
AAAAAA….A
Target mRNA
mRNA cleavage and degradation
RISC-bound antisense strand directed to target mRNA
AAAAAA….A
Target mRNARISC
© American Society for Investigative Pathology
![Page 58: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/58.jpg)
siRNA
www.nature.com/focus/rnai/animations/rnai_revised_320x180.mov
![Page 59: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/59.jpg)
Antisense ODN v.s. siRNA
Antisense ODN siRNA
Nucleotide sugar Deoxyribose Ribose
Structure Single stranded Double stranded
Length 16-30 bp 19-21 bp
Molecular weight ~ 6-9 kDa ~ 13-14 kDa
Precursor vailability No Yes
Site of action Cytoplasm / Nucleus Cytoplasm
mRNA cleavage RNase H RISC
Degradation upon activity Yes No
Effective concentration 50-400 nM 5-100 nM
![Page 60: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/60.jpg)
shRNA
Plasmid DNA
![Page 61: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/61.jpg)
miRNA
![Page 62: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/62.jpg)
cytoplasmic processing
Dicer (RNase III)
pre-miRNA
miRNA
Interact with target mRNA
RISCribosome
mRNA A(n)
RISC RISC
RISC RNA-Induced Silencing Complex
© American Society for Investigative Pathology
![Page 63: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/63.jpg)
miRNA
RNA-induced silencing complex
![Page 64: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/64.jpg)
General mechanisms of siRNA and miRNA
![Page 65: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/65.jpg)
siRNA v.s. miRNA
![Page 66: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/66.jpg)
siRNA v.s. miRNA
![Page 67: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/67.jpg)
Production and Regulation
Strict adherence to GLP and GMP principles
Effectiveness in an appropriate animal model
Safety in rodents and larger animals such as monkeys
Clinical Trials
Good Laboratory Practices
Good Manufacturing Processes
![Page 68: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/68.jpg)
Gene Therapy Successes
approved by the FDA for sale, some diseases have been experimentally successful:
• Melanoma (skin cancer)• Severe Combined Immunodeficiencies• Hereditary Blindness• Sickle Cell Anemia
![Page 69: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/69.jpg)
• 2006: Scientists at the National Institutes of Health (Bethesda, Maryland) have successfully treated metastatic melanoma in two patients. This study constitutes one of the first demonstrations that gene therapy can be effective in treating cancer.
• 2007- 2011: Research is still ongoing and the number of diseases that has been treated successfully by gene therapy increases.
Retinal disease Colour blindnessAdrenoleukodystrophy
• 2011: Medical community accepted that it can cure HIV as in 2008, Gero Hutter has cured a man from HIV using gene therapy
![Page 70: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/70.jpg)
Gene Therapy Disappointments
• In 1999 a boy died due to an immune response to an adenovirus gene therapy vector.
•Four children have developed cancer due to a retrovirus gene therapy vector
![Page 71: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/71.jpg)
You are now able to: Define the term “Gene Therapy” Use the correct terminology for gene transfer Realize the significance of gene therapy research
![Page 72: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/72.jpg)
Now you are able to: Describe the different strategies for gene therapy Select the suitable strategy based on the clinical case Understand the complexity of clinical application of gene therapy Evaluate proposed strategies according to the therapeutic need
![Page 73: Gene Therapy Dr. Aws Alshamsan & Dr. Nermin Hassan Department of Pharmaceutics aalshamsan@ksu.edu.sa nhassan@ksu.edu.sa](https://reader035.vdocuments.site/reader035/viewer/2022062308/56649e565503460f94b4ed00/html5/thumbnails/73.jpg)
http://www.wellesley.edu/Biology/Courses/219/Gen_news/i3_Gene_Therapy.jpg